Ginkgo Bioworks (DNA) vs Solid Biosciences (SLDB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Solid Biosciences (SLDB) has outperformed Ginkgo Bioworks (DNA) over the past year, gaining 24.1% versus a loss of 22.6%. Over five years, SLDB leads with a -79.7% price change compared with -97.6% for DNA. Ginkgo Bioworks is the larger company by market cap ($763.6 million vs $731.3 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | DNA | SLDB |
|---|---|---|
| Share price | $11.34 | $6.82 |
| Market cap | $763.64M | $731.28M |
| 1-day change | -1.13% | -0.44% |
| YTD return | +38.03% | +21.45% |
| 1-year return | -22.60% | +24.09% |
| 5-year return | -97.59% | -79.70% |
| EPS (TTM) | $-5.06 | $-1.89 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $18.22 | $11.45 |
| 52-week low | $5.37 | $3.79 |
| Distance from 52-week high | -37.76% | -40.44% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | -38.27% | +173.02% |
| Average volume | 1.77M | 1.09M |
| Shares outstanding | 55.38M | 107.23M |
| Employees | 485 | 121 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SLDB has outperformed DNA by 46.7 percentage points over the past year.
About Ginkgo Bioworks
DNA stock →Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 485 employees
About Solid Biosciences
SLDB stock →Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 121 employees
DNA vs SLDB FAQ
Which is bigger, Ginkgo Bioworks or Solid Biosciences?
Ginkgo Bioworks (DNA) is larger, with a market capitalization of $763.64M compared with $731.28M for Solid Biosciences (SLDB).
Which stock has performed better over the past year, DNA or SLDB?
SLDB returned +24.09% over the past 12 months, compared with -22.60% for DNA (price return, excluding dividends). Past performance does not predict future results.
Are Ginkgo Bioworks and Solid Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.